Previous 10 | Next 10 |
home / stock / polxf / polxf news
Polydex Pharmaceuticals press release ( OTCPK:POLXF ): Q2 GAAP EPS of -$0.09. Revenue of $1.09M (-18.7% Y/Y). For further details see: Polydex Pharmaceuticals GAAP EPS of -$0.09, revenue of $1.09M
Polydex Pharmaceuticals press release (OTCPK:POLXF): Q1 GAAP EPS of -$0.02. Revenue of $1.15M (+35.3% Y/Y). For further details see: Polydex Pharmaceuticals GAAP EPS of -$0.02, revenue of $1.15M
Polydex Pharmaceuticals press release (OTCPK:POLXF): FY GAAP EPS of -$0.16. Revenue of $4.23M (-13.0% Y/Y). For further details see: Polydex Pharmaceuticals GAAP EPS of -$0.16, revenue of $4.23M
TORONTO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to announce that it has entered into an agreement with Termanox Water Treatment Solutions for a novel use of its native dextran product. Termanox...
TORONTO, April 30, 2021 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (Pink Sheets: POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2021. All figures are reported in U.S. dollars. Management is satisfied with overall resul...
TORONTO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to report financial results for the third quarter of fiscal 2021, the period ending October 31, 2020. All figures are reported in U.S. dollars. T...
TORONTO, April 30, 2020 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2020. All figures are reported in U.S. dollars. Net income increased in fiscal year 2020 primarily d...
TORONTO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) announces 3 rd quarter financial results. Financial results for the third quarter of fiscal 2020, including the three-month and nine-month periods ended October 31, 2019, are shown together wit...
TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to report financial results for the second quarter of fiscal 2020, the period ending July 31, 2019. All figures are reported in U.S. dollars...
Polydex Pharmaceuticals ( OTCPK:POLXF ): Q3 GAAP EPS of $0.01. Revenue of $1.16M (-18.9% Y/Y) Press Release More news on: Polydex Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, ,
News, Short Squeeze, Breakout and More Instantly...
Polydex Pharms Ltd Company Name:
POLXF Stock Symbol:
OTCMKTS Market:
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...
Koss Corporation (KOSS) is expected to report for Q2 2024 Waterstone Financial Inc. (WSBF) is expected to report for Q4 2023 Silver Bull Resources Inc (SVBL) is expected to report for quarter end 2023-10-31 Xcel Energy Inc. (XEL) is expected to report $0.85 for Q4 2023 Sodexo ADR ...
Polydex Pharmaceuticals Inc (POLXF) is expected to report for quarter end 2023-10-31 RF Industries Ltd. (RFIL) is expected to report $-0.06 for Q4 2023 Northern Trust Corporation (NTRS) is expected to report $1.33 for Q4 2023 KeyCorp (KEY) is expected to report $0.22 for Q4 2023 S...